At a glance
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia.
Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.
Our lead product Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapy and is approved in the European Union, the United States and Switzerland for the treatment of iron deficiency with or without anaemia in adults. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. We are currently selecting a partner for the US where the product will be marketed as Accrufer®.